Ruditapes philippinarum is a member of the Veneridae family of marine bivalve molluscs. RPOI-1 (Ruditapes philippinarum oligopeptide) is a tetrapeptide that can be extracted from Ruditapes philippinarum by means of enzymolysis. This study showed that RPOI-1 strongly inhibits proliferation and induces apoptosis in DU-145 human prostate cancer cells. When cells were treated with varying concentrations of RPOI-1, significant inhibition of proliferation was detected by an MTT assay, and sub-G1 and G2/M phase cell cycle arrest was observed using flow cytometric (FCM) analysis. Furthermore, morphological changes characteristic of apoptosis and an increase in the proportion of apoptotic cells were observed using double sequential acridine orange/ethidium bromide staining, FCM analysis and transmission election microscopy. FCM studies showed that exposing DU-145 cells to 10, 20 and 30 mg/ml RPOI-1 for 24 h increased the percentage of cells in the early-stages of apoptotis in a dose-dependent manner, with the numbers rising from 3.01% in the control group to 13.40% in the group treated with the highest dose.
Introduction
Ruditapes philippinarum, a member of the Veneridae family, is predominantly found along the coasts of the Philippines, Japan and China. It is an intertidal bivalve, which preferentially inhabits the inner bay. It has a high commercial value and is also an important aquaculture species in intertidal zones. RPOI-1 (Ruditapes philippinarum oligopeptide), is a water-soluble tetrapeptide that can be extracted from Ruditapes philippinarum by means of enzymolysis.
A number of studies have demonstrated that certain products from marine sources, including Sepia ink, Dolabella auricularia, Mactromeris polynyma and Halichondria okadai, have significant anticancer activity (1) (2) (3) (4) . Sepia ink oligopeptide (SIO) is an antitumor tripeptide that was first isolated from Sepia esculenta using enzymolysis. SIO was shown to significantly inhibit the proliferation of DU-145, PC-3 and LNCaP human prostate cancer (PCa) cells in a time-and dose-dependent manner (5) . SIO has been shown to induce apoptosis in prostate cancer cell lines via activation of caspase-3 and elevation of the Bax/Bcl-2 ratio (5).
PCa is the most common type of malignancy worldwide and second only to lung cancer as the leading cause of cancer-related mortality (6) . During the early stages of PCa, growth of prostatic epithelial cells is androgen-dependent. Therefore, hormone therapy has been an initial option with which to treat patients with PCa. However, tumor cells ultimately become androgen-independent, necessitating the development of different forms of treatment (7) . Cytotoxic chemotherapy aims to kill cancer cells, but is not a targeted treatment, and therefore also affects healthy cells. Dox (doxorubicin) has potent and broad-spectrum therapeutic activity against PCa. Despite its effectiveness, the use of Dox is limited, as concentrations required to kill cancerous cells cannot be employed without causing systemic toxicity (8) .
Numerous interventions have been tried in order to remove cancerous tissues, including surgery and chemotherapy, without universal success (9) . In addition, many cancer drugs exhibit a relatively short clinical life span and become ineffective, due to the development of resistance. Furthermore, a number of potent drugs frequently cause serious side effects. Therefore, there is an urgent requirement to identify and develop novel anticancer agents that are safe and effective (10) . The present study evaluated the anticancer activity and mechanisms of action of RPOI-1 against prostate cancer in a Du-145 PCa cell line. The objectives of the current study were to investigate the antiproliferative effects of RPOI-1 against DU-145 cells and to clarify whether apoptosis and cell-cycle arrest were involved in any observed anticancer activity.
Materials and methods
Materials. Ruditapes philippinarum was collected from the Zhoushan coastal area. DU-145 human prostate cancer cells were obtained from the Cell Bank of the Chinese Academy of Science (Shanghai, China). The ultrafiltrate was applied to a column saturated in diethyaminoethyl (DEAE)-sepharose fast flow (FF; Amersham Pharmacia Biotech, Shanghai, China). The Ruditapes philippinarum peptide fraction was further purified using reverse-phase high performance liquid chromatography (HPLC) on a Primesphere C18 column (Phenomenex Co., Ltd., Shanghai, China). The degree of inhibition of proliferation of DU-145 cells was detected by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Hangzhou Haotian Biotechnology Co., Ltd., Hangzhou, China). F-12 medium, fetal bovine serum (FBS) and an Annexin V-fluorescein isothiocyanate (FITC) apoptosis detection kit were purchased from BD Biosciences (Franklin Lakes, NJ, USA). Other reagents were of analytical grade and produced in China.
Enzymatic hydrolysis. Ruditapes philippinarum tissues were homogenized and digested with protease at 45˚C using trypsin [300 U/g, pH 7.0; solid-liquid ratio (w/v), 1:3] for 6 h. Following enzymatic hydrolysis, the mixture was immediately heated to 95˚C for 15 min in order to inactivate the enzyme. The hydrolysates were clarified by centrifugation at 8580 x g for 20 min to remove the unhydrolyzed residue.
Isolation and purification of the anticancer peptide
Ultrafiltration. The Ruditapes philippinarum hydrolysate (RH) filtrate was filtered through a 3 kDa molecular weight cut-off membrane (Amicon Ultra-15; Millipore, Billerica, MA, USA). It was then fractionated into two ranges of molecular weight (RH1>3 kDa and RH2≤3 kDa). The respective permeates were lyophilized and their antitumor activity was measured using an MTT assay.
DEAE-sepharose FF ion exchange chromatography. The lyophilized fraction exhibiting the highest antitumor activity was dissolved in 0.05 mmol/l Tris/HCl buffer (pH 7.4) and applied to a DEAE-sepharose FF column (115x50 mm), which had previously been equilibrated with the same buffer. The column was eluted with a linear gradient of NaCl concentrations in Tris/HCl buffer from 0 to 1.0 mol/l. Fractions of 4 ml were collected at a flow rate of 2 ml/min. Chromatography was performed using an ÄKTA-explorer system (GE Healthcare, Little Chalfont, UK) and the elution peaks were monitored at 280 nm.
Reverse-phase (RP)-HPLC. The fraction exhibiting the highest anticancer activity was further purified using reverse-phase HPLC on a Primesphere C18 column (10x250 mm) with a linear gradient of acetonitrile (0-50% for 20 min) containing 0.1% trifluoroacetic acid at a flow rate of 1 ml/min. The absorbance of eluent was monitored at 280 nm.
DU-145 cell culture. DU-145 cells were cultured in F-12 medium, supplemented with 10% FBS (v/v), 2 mM glutamine, 100 IU/ml penicillin and 100 IU/ml streptomycin. Cultures were maintained in a humidified incubator at 37˚C, with 5% CO 2 and 95% air.
Antiproliferative activity using an MTT assay. The cytotoxicity of RPOI-1 against the DU-145 cells was assessed using a colorimetric MTT assay. DU-145 cells were seeded (1x10 5 cells/ml) together with various concentrations of the RPOI-1 sample (10, 15, 20, 25 and 30 mg/ml) and incubated for up to 24, 48 or 72 h prior to MTT treatment. A stock solution of 50 µl of 2 mg/ml MTT in phosphate-buffered saline (PBS) was added to each well to achieve a total reaction volume of 250 µl. Following 5 h incubation, the formazan crystals in each well were dissolved in dimethyl sulfoxide. The quantity of purple formazan was assessed by measuring the absorbance at 490 nm using an enzyme-linked immunosorbent assay reader (Thermo Multiskan Spectrum; Thermo Electron Corporation, Dreieich, Germany).
Morphological analyses. DU-145 cells in the exponential growth phase were plated at 1x10 4 cells/well in 6-well plates. Following 24 h growth, cells were treated with RPOI-1 at 10, 20 or 30 mg/ml for 24 h. At the end of the treatment, the effect of RPOI-1 on the morphology of the DU-145 cells was assessed by the inverted and phase-contrast microscope (Olympus Corporation, Tokyo, Japan) at x200 magnification.
Annexin V-FITC/propidium iodide (PI) double-staining analysis.
Annexin V-FITC/PI double-staining analysis was used to evaluate the induction of apoptosis in cancer cells by RPOI-1. Exposed phosphatidylserine on the outside of apoptotic cells was determined using the Annexin V-FITC Apoptosis kit. To detect the early and late stages of apoptosis, as well as necrosis induced by RPOI-1, the DU-145 cells were plated at a density of 1x10 5 cells/well in 6-well plates and incubated for 24 h at 37˚C in 5% CO 2 . Cells were harvested by centrifugation at 4,000 x g for 7 ; they were then washed with ice-cold PBS twice and stained with 10 µl PI and 5 µl Annexin V-FITC at room temperature for 15 min in darkness. Annexin V-FITC and PI emissions were detected in the FL1 and FL2 channels of a FACSCalibur flow cytometer (Becton-Dickinson, San Jose, CA, USA). The distribution percentages of normal cells, necrotic cells, and cells in the early and late stages of apoptosis were calculated by Cell-Quest software (BD Biosciences, Franklin Lakes, NJ, USA).
Cell cycle analysis. Flow cytometric analyses were conducted in order to determine the proportion of apoptotic sub-G1 hypodiploid cells. DU-145 cells were placed in 6-well plates at a concentration of 1x10 5 cells/ml for 16 h and treated with 10 or 30 mg/ml RPOI-1. Following incubation for 24 h, the cells were harvested, as previously described, at the indicated times and fixed for 30 min in 1 ml of 70% ethanol at 4˚C. The cells were then washed twice with PBS and incubated for 30 min in darkness in 1 ml PBS containing 100 µg PI and 100 µg RNase A (Sigma, St. Louis, MO, USA), at 37˚C. Flow cytometric analysis was conducted using a FACS Calibur flow cytometer (Becton Dickinson). Effects on the cell cycle were determined by measuring changes in the percentage of cell distribution at each phase of the cell cycle and were assessed by histograms generated by the Cell Quest and Mod-Fit computer programs (Verity Software House, Topsham, ME, USA).
Statistical analysis. Data are expressed as the mean ± standard deviation. Significance was determined by an unpaired Student's t-test using SPSS 16.0 software (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.
Results and Discussion
The lyophilized trypsin digestion was dissolved in Tris/HCl buffer (0.05 mmol/l, pH 7.14) and loaded onto a DEAE-Sepharose FF column with a linear gradient of NaCl (0.01 mol/l). As shown in Fig. 1 , the elution peaks were monitored at 280 nm, and two major fractions (RPOI and RPOII) were identified. Due to the higher anticancer activity of RPOI, this molecule was further separated using reverse-phase HPLC. As shown in Fig. 2 , peak 4 was collected and termed RPOI-1. Its sequence was identified as N-Asp-Trp-Pro-His, with a molecular mass of 607.6 kDa. The amino-acid backbone of RPOI-1 is shown in Fig. 3 .
Evaluation of RPOI-1 for potential anticancer activity on DU-145 cells was conducted by investigating its inhibitory effects on cell growth using an MTT assay. As shown in Fig. 4 , RPOI-1 inhibited DU-145 cell proliferation in a dose-and time-dependent manner. Furthermore, RPOI-1 exhibited >90% cell proliferation inhibition at a concentration of 30 mg/ml following 72 h treatment.
Morphological observation of apoptotic cells by fluorescence microscopy using acridine orange (AO) staining is a well-established biological assay for detecting apoptotic cells.
Apoptosis, also termed programmed cell death, is characterized by typical cellular morphology and biochemical features, including cell shrinkage, cytoplasm vacuolization, chromatin condensation, DNA fragmentation and ultimately cellular breakdown into apoptotic bodies (11) .
To clarify whether the cell death of RPOI-1 treated cells occurred via induction of apoptosis, the presence of apoptotic features in the treated cells was confirmed by double AO/ethidium bromide staining.
As a control, DU-145 cells were cultured in complete media and stained with AO/EB (Fig. 5A) . Viable cells appear homogeneous, with bright green nuclei and an intact structure, as shown in Fig. 5A . As displayed in Fig. 5B , early apoptotic cells contained green nuclei, but perinuclear chromatin condensation was also visible as bright green patches or fragments. Fig. 5C and D show cells in later stages of apoptosis, which contain orange-red nuclei with condensed or fragmented chromatin, and necrotic cells, which contained a homogeneous orange-red nuclei with an intact structure.
These changes indicated that RPOI-1 may induce DU-145 cell apoptosis. More apoptotic cells in later stages of apoptosis were observed with higher concentrations of RPOI-1. In order to quantify the proportion of cells that had undergone apoptosis, DU-145 cells were treated with RPOI-1 for 24 h, followed by simultaneous staining with Annexin V-FITC and PI and analyzed by BD FACSCalibur flow cytometry. Annexin V-FITC/PI double-staining analysis demonstrated that the treatment with RPOI-1 decreased the number of healthy DU-145 cells in a dose-dependent manner. As shown in Fig. 6 , the number of apoptotic cells in the early and late stages of apoptosis increased in a dose-dependent manner from 3.01 to 13.40% and from 2.69 to 24.20% at the highest dose, respectively.
Transmission electron microscopy is the preferred method for morphological observation by which to clearly differentiate nuclei and organelles. It was used to confirm apoptosis in DU-145 cells in this study. As shown in Fig. 7A , there were no typical morphological changes of apoptosis observed in control cells. However, when cells were exposed to RPOI-1 for 48 h, characteristic apoptotic morphological changes were observed, as shown in Fig. 7B and C. These results demonstrate that RPOI-1 induced apoptosis in DU-145 cells. Following 48 h of incubation with 10 mg/ml RPOI-1, the nuclei were shrunken, irregularly shaped and chromatin was highly condensed at the nuclear periphery. Furthermore, apoptotic bodies were observed in the cytoplasm following treatment with 30 mg/ml RPOI-1 for 48 h. In addition, overall cell size was reduced and the nuclei were shrunken. These findings were highly suggestive of apoptosis in those cells exposed to RPOI-1. However, characteristics of necrotic change, such as swelling of cytoplasm or intracytoplasmic organelles, were not observed. Table I . Percentage of DU-145 cells in sub-G1, G0/G1, S and G2/M phases. Cancer is a disease state characterized by disordered proliferation and the inhibition of apoptosis. The uncontrolled cellular growth and proliferation that distinguishes cancer cells from normal cells are key processes in carcinogenesis (12) . The inhibition of proliferation and induction of apoptosis are efficient methods by which to treat tumors (13) . For example, a number of anticancer agents induce cell death by interfering with processes in the cell cycle (14) and others lead to cell death by increasing apoptosis (15) .
DU-145 cells (%)
In order to quantify the induction of apoptosis by RPOI-1 treatment, flow cytometric analysis was conducted. As shown in Fig. 8 , the percentage of cells in the sub-G1 phase was 0.66% in the control group. However, as shown in Fig. 7 , RPOI-1 treatment in the DU-145 cells at concentrations of 10 or 30 mg/ml induced a dose-dependent increase in the proportion of cells in different phases of the cell cycle, as reflected in the change in the percentage of cells in the sub-G1 phase (3.67 and 5.74%, respectively). Table I shows that there was a significant increase from 0.66±0.61 to 5.74±0.59% in the sub-G1 phase and from 31.10±1.67 to 48.67±2.40% in the G2/M phase in DU-145 cells treated with 30 mg/ml RPOI-1. These results demonstrate that RPOI-1 induced G2 phase arrest and apoptosis in DU-145 cells.
In conclusion, RPOI-1 had a toxic effect on DU-145 cells and typical apoptotic morphological changes were observed with AO/EB staining, FCM analysis and TEM. The present study demonstrated that RPOI-1 inhibited DU-145 cell proliferation through induction of the apoptotic pathway and that Ruditapes philippinarum may possess anticancer properties. To the best of our knowledge, these findings demonstrate for the first time the anticancer potential of Ruditapes philippinarum. This evidence for biological activity in the Ruditapes philippinarum extract indicates that its consumption may be beneficial to health. In addition, the findings of this study may increase awareness regarding the potential anticancer properties of RPOI-1 and aid future developments in anticancer therapeutics on an industrial scale.
